http://probaseweb.com/bimedaie/media/k2/attachments/Boviseal_Data_Sheet

PRODUCT INFORMATION

BOVISEAL Bismuth Subnitrate 2.6g

BENEFITS •

•

• •

• •

Seals the teat from the moment of drying off until calving Protection for the entire dry cow period thus reducing cases of dry cow mastitis Less cases of mastitis in the next lactation Proven efficacy in mastitis prevention through trial work and customer satisfaction Nil milk withdrawal when used on it’s own Can be combined with any other dry cow tube for a synergistic approach to mastitis prevention and control

PACKAGING LIST NO.

UNIT PACKAGE

1BOV010

120 SYRINGES

CASE SIZE 1

See reverse side for full indications, administration and dosage.

Bimeda® a division of the Cross Vetpharm Group Ltd. Broomhill Road I Tallaght I Dublin 24 I Ireland Tel: 1850-515253 Fax: 01 451 5803 Web: www.bimeda.ie

TECHNICAL PRODUCT INFORMATION INFORMATION

BOVISEAL NA Presentation Boviseal is an off-white smooth paste. It is presented in syringes each containing 4 g intramammary infusion containing 65% Bismuth Subnitrate, in a mineral oil vehicle.

Uses Boviseal is indicated for the prevention of new intramammary infections throughout the dry period. This results in a reduction in the incidence of sub clinical mastitis in cows at calving, and of clinical mastitis in the dry period and the subsequent lactation (for at least 60 days after calving).

It is recommended that Boviseal be used as part of a herd approach to dry cow management and mastitis control. Cows considered likely to be free of sub clinical mastitis should be given Boviseal at drying off according to the criteria below. Other animals should be managed in accordance with an approved mastitis control plan or specific veterinary advice.

For practical purposes, selection criteria may be based on the mastitis and cell count history of individual cows, or recognised tests for the detection of sub clinical mastitis or bacteriological sampling. It is particularly important that, prior to treatment, an individual cell count be obtained from any cow with a history of clinical mastitis during the previous lactation. As a guide, cows with an average cell count less than 200,000 cells/ml before drying off may be given Boviseal. A minor increase (cell count up to 250,000 cells/ml) during the last 4 weeks before drying off is normal and may be ignored. In case of doubt, veterinary advice should be sought Dosage and Administration Dosage One syringe into each udder quarter immediately after the last milking of the lactation (at drying off).

Administration At drying off the teat should be thoroughly cleaned and disinfected, and it should be allowed to dry before infusion; this is essential, as Boviseal possesses no antimicrobial activity.

Care should also be taken to avoid contamination of the syringe nozzle.

Insert nozzle into the teat and apply gentle and continuous pressure until the paste is expressed.

Do not massage the teat or udder after infusion of the product. It is advisable to use an appropriate teat disinfectant following the infusion.

Contra-indications, Warnings, etc.

Not intended for use in cows with a suspected or confirmed intramammary infection at drying off.

Do not use in the lactating cow. If lactating cows are accidentally infused the seal can easily be stripped out manually and no additional precautions are needed.

If a sealed quarter develops clinical mastitis the affected quarter should be stripped out manually before appropriate antibacterial therapy is instituted.

For single use only.

Withdrawal Periods Meat and offal: zero days Milk: zero days Pharmaceutical Precautions Keep out of the reach and sight of children.

For animal treatment only.

Legal Category

LM

Package Quantities 120 syringes.

Further Information Most of the seal comes out at the first stripping, suckling or milking after calving, but small amounts may occasionally be seen for a few days as flecks on the filter.

Boviseal can be differentiated from mastitis by its texture.

Under cold conditions the product may be warmed to room temperature in a warm environment, to aid syringeability. Individual tubes must not be placed in warm water.

Any unused product or waste material should be disposed of in accordance with national requirements.

Operator Warnings No special precautions.

VPA No.

10960/49/1

Bimeda速 a division of the Cross Vetpharm Group Ltd. Broomhill Road I Tallaght I Dublin 24 I Ireland Tel: 1850-515253 Fax: 01 451 5803 Web: www.bimeda.ie